antisense oligonucleotide (ASO)

Eric Welin May 9, 2023May 9, 2023

An antisense oligonucleotide (ASO) is a short, synthetic strand of DNA or RNA designed to bind to a specific target RNA molecule, thereby modulating its function or expression. This can be used to regulate gene activity in the context of research or therapeutic applications.

Synonyms:

antisense oligonucleotide, ASO

Alternative Splicing in White Blood Cells: A Biomarker for Fragile X Syndrome
Explore groundbreaking research by the University of Massachusetts Medical School and Rush University Medical Center on alternative splicing in white blood cells as a biomarker for Fragile X syndrome, paving the way for personalized treatment optimization through a non-invasive blood test.
FRAXA Annual Appeal – Rewrite the Future for Fragile X Families
This year, FRAXA-funded researchers have made a transformative discovery that could change the future for Grant and all families impacted by Fragile X.
Breakthrough Discoveries in Fragile X Research: Insights from Special Banbury Meeting on Curative Therapies
Explore the latest breakthroughs in Fragile X research unveiled at the recent Banbury Meeting. Discover novel strategies, from gene therapy to protein replacement, that bring hope for curative therapies.
Innovative Breakthrough in Fragile X Treatment: The Promise of Antisense Oligonucleotide (ASO) Therapy
This changes everything! FRAXA funded research introduces Antisense Oligonucleotide (ASO) Therapy, redefining Fragile X syndrome treatment and understanding.
ASOs and Fragile X: Addressing the Most Asked Questions
Explore the potential of ASOs in treating Fragile X syndrome & FXTAS. Dive into a comprehensive Q&A addressing key questions and breakthrough findings.

« Back to Glossary Index